Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Lynsey Robson.

Newcastle AuthorsTitleYearFull text
Professor Ruth Plummer
Dr Christopher Jones
Professor Nicola Curtin
Professor Alan Boddy
Professor Herbie Newell
et al.
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors2008
Professor Ruth Plummer
Professor Alan Boddy
Professor Nicola Curtin
Professor Herbie Newell
Lynsey Robson
et al.
Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide2005
Professor Ruth Plummer
Dr Christopher Jones
Lynsey Robson
Professor Alan Calvert
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors2005
Dr Mark Verrill
Professor Alan Boddy
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors2003
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study2002
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Kevin Fishwick
et al.
Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate2001
Professor Alan Boddy
Huw Thomas
Lynsey Robson
Professor Alan Calvert
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer1997
Professor Alan Boddy
Huw Thomas
Professor Herbie Newell
Professor Alan Calvert
Lynsey Robson
et al.
Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study1996
Kevin Fishwick
Lynsey Robson
Professor Alan Calvert
Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer1996
Professor Alan Calvert
Professor Alan Boddy
Dr Andrew Hughes
Lynsey Robson
Huw Thomas
et al.
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.1995
Lynsey Robson
Professor Alan Calvert
Oral folic acid improves lometrexol toxicity profile: A phase I study1995